Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE) - Wikidata - wikimedia - TriplyDB

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)

http://www.wikidata.org/entity/Q33835874

about

A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial.

P2860

Q55399757-34F3B68A-8DBC-49FA-93E4-366DA3A78632

P2860

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)

http://www.wikidata.org/entity/Q33835874

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Cardiovascular safety in refra ...... herapy to solifenacin (BESIDE)

@ast

Cardiovascular safety in refra ...... herapy to solifenacin (BESIDE)

@en

type

label

Cardiovascular safety in refra ...... herapy to solifenacin (BESIDE)

@ast

Cardiovascular safety in refra ...... herapy to solifenacin (BESIDE)

@en

prefLabel

Cardiovascular safety in refra ...... herapy to solifenacin (BESIDE)

@ast

Cardiovascular safety in refra ...... herapy to solifenacin (BESIDE)

@en

P1433

Q33835874-CDCD524E-86C4-4756-98A5-FAAC305D2B93

P1476

Q33835874-0BA851CB-8F32-465A-BC11-67999413CA06

P2093

Q33835874-044F22EC-4FBA-4870-94C0-1DA982171D13

Q33835874-0B185C16-9B54-4A9E-A5DA-108A3811E2A3

Q33835874-2417FD8A-94B7-4D53-AD60-BB6C7D4EA07F

Q33835874-35F51BB1-941E-40FC-9D2B-E5B251F5FD2A

Q33835874-53D96853-16AF-4C56-8F8B-B459D76FAEE2

Q33835874-672DE7BC-CEF2-41A2-A876-8EECA39093E6

Q33835874-720A23C5-5AD2-4852-9DA2-498CE75E0F0A

Q33835874-AE6FA946-00BB-413C-9E7E-DA1DF7297E5D

Q33835874-C424548A-1ECB-4AB1-B6DE-88203F9F4114

Q33835874-DC27F357-2419-495D-8344-DC7222EC632E

P2860

Q33835874-157EA77B-8DD9-4D1F-A600-AC187751376E

Q33835874-1FB06540-3405-4306-BD37-030C93F80C6D

Q33835874-2317663A-337B-4540-8518-32FC99A01483

Q33835874-27D005B9-175D-4594-A951-8D0C0B9FD60B

Q33835874-2887BEDE-3387-40E2-8617-C81A4BDC60DE

Q33835874-2AE51FCC-ED9E-4C01-AFDC-7283C40AC848

Q33835874-2B827A86-8252-426E-885D-12A25280FEEC

Q33835874-2DABC53D-225D-4149-8A07-E226E5AF198D

Q33835874-70013065-387D-4875-9664-B5DEAC532D2C

Q33835874-7DDBBFE2-A324-409B-B5D9-36B1E7A2A721

P31

Q33835874-7766D06B-D6F6-4B47-94D1-95F2F69E0884

P356

Q33835874-6B724FB6-14B8-4EF6-B506-C8F75AB80A27

P433

Q33835874-98E9DEBD-E331-45BB-98FB-EF5491B6C11B

P478

Q33835874-39432552-C76C-436D-B168-6EC2F4161E0D

P50

Q33835874-3B1DB7F7-B5A2-4D73-9610-3CD365A07E13

P577

Q33835874-23431FE3-6992-46C8-8B45-33EBA34CD505

P698

Q33835874-15FBAAF8-E8AD-4689-A3AB-1F5453C74C93

P932

Q33835874-B7C054FA-EAFB-46EC-A1BC-36A4093CCDCC

P356

P1433

International Journal of Clinical Practice

P1476

Cardiovascular safety in refra ...... herapy to solifenacin (BESIDE)

@en

P2093

Adil Esen

http://www.w3.org/2001/XMLSchema#string

Christopher R Chapple

http://www.w3.org/2001/XMLSchema#string

David Mitcheson

http://www.w3.org/2001/XMLSchema#string

Emad Siddiqui

http://www.w3.org/2001/XMLSchema#string

Javier Cambronero Santos

http://www.w3.org/2001/XMLSchema#string

Marcus J Drake

http://www.w3.org/2001/XMLSchema#string

Matthias Stoelzel

http://www.w3.org/2001/XMLSchema#string

Moses Huang

http://www.w3.org/2001/XMLSchema#string

Scott MacDiarmid

http://www.w3.org/2001/XMLSchema#string

Sender Herschorn

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome

What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women.

Adrenergic and muscarinic receptors in the human heart.

Resting pulse rate reference data for children, adolescents, and adults: United States, 1999-2008.

The prevalence of overactive bladder.

The muscarinic receptor subtypes in human blood vessels.

Gender differences in arrhythmias.

Prevalence and burden of overactive bladder in the United States.

Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.

P31

scholarly article

P356

10.1111/IJCP.12944

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Stavros Athanasiou

P577

2017-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28419650

http://www.w3.org/2001/XMLSchema#string

P932

5485167

http://www.w3.org/2001/XMLSchema#string